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Advances in apoptosis research
Abstract
Apoptosis, also called programmed cell death, has attracted great attention in recent years. After its
discovery by Carl Vogt in 1842, apoptosis research was dormant for more than a century. Its rediscovery
in the second half of this century, and the coining of the term apoptosis in 1972 by Kerr, Wyllie, and
Currie, ignited an unparalleled interest in this field of science. The number of publications related to
apoptosis has been growing exponentially every year ever since. This is mainly due to three major
advances, two of which have been made recently and one that is currently seen. First, studies with the
small nematode Caenorhabditis elegans have identified a number of apoptosis regulating genes--the first
evidence that cell death is an active process under genetic control. Many of these genes have
mammalian homologs that, like their worm counterparts, seem to regulate mammalian apoptosis.
Second, elucidation of the signal transduction pathways of apoptosis has lead especially to the
identification of specific death signaling molecules such as a new family of cysteine proteases, the
caspases. Third, it has now become clear that many diseases are characterized by dysregulation of
apoptotic programs. Many of these programs involve a family of receptors and their ligands, the death
receptor/ligand family. The hope now is to interfere with apoptosis regulation in these systems and to
develop new therapeutic concepts.
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ABSTRACT Apoptosis, also called programmed cell
death, has attracted great attention in recent years. After its
discovery by Carl Vogt in 1842, apoptosis research was
dormant for more than a century. Its rediscovery in the second
half of this century, and the coining of the term apoptosis in
1972 by Kerr, Wyllie, and Currie, ignited an unparalleled
interest in this field of science. The number of publications
related to apoptosis has been growing exponentially every year
ever since. This is mainly due to three major advances, two of
which have been made recently and one that is currently seen.
First, studies with the small nematode Caenorhabditis elegans
have identified a number of apoptosis regulating genes—the
first evidence that cell death is an active process under genetic
control. Many of these genes have mammalian homologs that,
like their worm counterparts, seem to regulate mammalian
apoptosis. Second, elucidation of the signal transduction
pathways of apoptosis has lead especially to the identification
of specific death signaling molecules such as a new family of
cysteine proteases, the caspases. Third, it has now become
clear that many diseases are characterized by dysregulation of
apoptotic programs. Many of these programs involve a family
of receptors and their ligands, the death receptoryligand
family. The hope now is to interfere with apoptosis regulation
in these systems and to develop new therapeutic concepts.
The first of three recent breakthroughs in apoptosis research
comes from the genetic study of genes that control apoptotic
cell death in the nematode Caenorhabditis elegans. In the worm
three genes—ced-3, ced-4, and ced-9—are directly involved in
controlling the execution of apoptosis during development (1).
Both ced-3 and ced-4 are killer genes, required for the cell to
die, whereas ced-9 is a survival gene required to protect C.
elegans cells that should survive from inappropriately activat-
ing the death program. Interestingly, homologs of these genes
also function to control apoptosis in mammals: ced-3 encodes
a protease homologous to the mammalian caspase family.
CED-3 activity is negatively regulated by CED-9, which is
structurally and functionally homologous to Bcl-2, a mamma-
lian protein that has been shown to inhibit many forms of
apoptosis, and other Bcl-2 family members such as Bcl-xL. To
exert its function, CED-9 requires the presence of CED-4,
another apoptosis-promoting factor, which acts as a physical
bridge between CED-9 and CED-3 and is essential for the
processing of proCED-3 (an inactive zymogen) into the cat-
alytically active death enzyme. Apaf-1, a recently identified
CED-4 homolog, is similarly required for the processing of
caspase-3 in mammalian cells (2). The conservation in both
sequence and function between nematode and mammalian cell
death genes indicates that apoptosis is of ancient evolutionary
origin, and it suggests that worms and humans use similar
conserved mechanisms to get rid of cells.
A large number of additional genes have also been identified
in C. elegans that affect other aspects of apoptotic death. Many
of these genes, such as ced-1, -2, -5, -6, -7, and -10, act distally
of the central apoptotic machinery in the cell. These genes are
required for efficient recognition and phagocytosis of apopto-
tic cells by their neighbors. Some genes, such as ces-1 and ces-2,
function only in a small number of cells and affect the decision
of individual cells to activate the death program. These genes
might be involved in cell type-specific ‘‘private’’ signal trans-
duction pathways or regulatory cascades that affect the cell
death pathway. The ces-2 gene has recently been shown to
encode a homolog of the human oncogene Hlf (hepatic
leukemia factor) (3). Interestingly, both CES-2 and Hlf func-
tion as cell type-specific negative regulators of cell survival,
suggesting that not only the central killing machinery but also
the inputs into this machinery have remained conserved
through evolution.
The second breakthrough is related to the discovery of a
family of receptors that can specifically trigger apoptosis.
These receptors belong to the tumor necrosis factor (TNF)
receptor superfamily and are characterized by the presence of
extracellular cysteine-rich domains. Intracellularly, however,
these members contain an area of weak homology required to
transduce a cell death signal which was termed the death
domain (DD). With the discovery of genuine death receptors
the importance of apoptosis induction became most obvious.
Members of this new family include CD95 (APO-1yFas),
TNF-R1, DR3 (TRAMPywsl-1yAPO-3yLARDyAIR), and
DR4yTRAIL-R1yAPO-2 (for review see ref. 4). The DD
couples the death receptors to the apoptosis-inducing machin-
ery. A number of signaling molecules carry a DD that directly
binds to these receptors. These molecules include FADDy
MORT1, TRADD, RIP, RAIDDyCRADD, and MADD.
Only some of them, however, have been detected as part of an
in vivo complex with their receptors formed in a ligand-
dependent fashion. FADD was found to be part of the CD95
death-inducing signaling complex (DISC), and TRADD was
found associated with TNF-R1 upon binding of TNFa. DD-
containing molecules are specialized adapter molecules cou-
pling to the apoptosis executioners, which are in many in-
stances members of the caspase family of proteases. The
best-characterized member of these receptor-binding caspases
is caspase-8yFLICEyMACHyMch5. Caspase-8 is recruited to
the CD95 DISC by the adaptor FADD. At its N terminus,
FADD contains a death effector domain (DED), a motif that
was also found in two copies at the N terminus of caspase-8.
Caspase-8 is activated by binding to the DISC (5). The active
subunits p10yp18 are released into the cytoplasm, likely
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cleaving various death substrates that still need to be identi-
fied.
The elucidation of the apoptosis pathway in C. elegans has been
helpful to better understand apoptosis signaling pathways in
higher eukaryotes. Key components of the apoptosis machinery
seem to be conserved between humans and nematodes. However,
neither an apoptosis-inducing receptor nor coupling adaptor
molecules have yet been identified in C. elegans (Fig. 1). In human
cells, at least 10 caspases are expressed, all of which contain
regions homologous to the C. elegans CED-3. Recent data
indicate that some of these caspases, such as caspase-8, act
upstream of the human CED-9 homolog Bcl-2yBcl-xL, whereas
others, such as caspase-3, seem to be located downstream of
Bcl-2yBcl-xL in the pathway. The latter caspases may require a
protein similar to the nematode CED-4 protein for their activa-
tion—e.g., the recently identified Apaf-1 (Fig. 1).
The third reason why apoptosis research has experienced
such a rapid development relates to its biological relevance.
Apoptosis is the physiological way for nucleated cells to die.
Apoptosis takes care of unwanted, injured, or virus-infected
cells. Autoreactive T and B cells, millions of which are
produced by the immune system every day, are also eliminated
by apoptosis. Recently, dysregulation (‘‘too much or too little’’)
of apoptosis has emerged as a new concept to explain impor-
tant features in the development of several as yet poorly
understood diseases (Table 1). Unregulated excessive apopto-
sis may be the cause of various degenerative and autoimmune
diseases that are characterized by an excessive loss of normal
or protective cells, such as in multiple sclerosis, type-I diabetes
mellitus, Hashimoto thyroiditis (6), Sjo¨gren syndrome, and
certain cancers such as melanoma (7). Conversely, an inap-
propriately low rate of apoptosis may promote survival and
accumulation of abnormal cells that can give rise to tumor
formation and prolonged autoimmune stimulation such as in
cancers and Graves disease. Remarkably, even within the same
organ such as the thyroid gland, entirely different states of
disease may be initiated depending upon the rate at which
apoptosis continues to proceed. For instance, in the atrophic
variant of immunogenic hypothyroidism (Hashimoto thyroid-
itis), infiltrating immune effector cells may trigger apoptosis in
target cells within thyroid follicles by means of the CD95y
CD95L system (6). Moreover, upon exposure to interleukin-1,
thyroid follicular cells also appear to use the CD95yCD95L
system to transmit the apoptotic signal onto their neighboring
cells. By contrast, in the autoimmune hyperthyroidism of
Graves disease, intrathyroidal fibroblasts have been identified
to act as potent inhibitors of the apoptotic machinery of
intrathyroidal B lymphocytes, thereby enhancing their life
span, differentiation, and immunoglobulin secretion within the
diseased gland. In studies of the mechanisms of fibroblast-
mediated suppression of lymphocyte apoptosis, coculture ex-
periments with intrathyroidal fibroblasts and B cells have
revealed that both fibroblast-derived soluble factors and direct
cell contact most effectively inhibit apoptosis in intrathyroidal
B cells (8). It seems likely that pro- and anti-apoptotic factors
determine either susceptibility or resistance to apoptosis, and,
consequently, play a crucial role in the evolution, propagation,
and chronicity of degenerative, cancerous, and autoimmune
conditions. Thus, precise identification of the distinct errors in
the complex apoptotic machinery holds great promise for
elucidating the pathogenesis of various important diseases and
for devising more specific and effective treatments.
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FIG. 1. C. elegans apoptosis-regulating genes and their human homologs.
Table 1. Apoptosis in disease
Too much Too little
AIDS Canale–Smith syndrome
Cancers (e.g., melanoma, hepatoma
colon cancer)
(CSS; autoimmune
lymphoproliferative
syndrome)
Liver failure Lymphoma
Wilson disease Leukemia
Myelodysplastic syndromes Solid tumors
Neurodegenerative diseases
Multiple sclerosis
Aplastic anemia
Chronic neutropenia
Type I diabetes mellitus
Autoimmune diseases
(e.g., hypereosinophilia
syndrome, lupus
erythematosus,
rheumatoid arthritis,
Hashimoto thyroiditis Graves disease)
Ulcerative colitis
Listed are diseases in which dysregulation of apoptosis has been
shown or is currently being discussed as being involved.
From the Academy: Peter et al. Proc. Natl. Acad. Sci. USA 94 (1997) 12737
